



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07K 14/47, A61K 38/10, 38/16</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/00270</b> <b>(43) International Publication Date:</b> 3 January 1997 (03.01.97)
<b>(21) International Application Number:</b> PCT/EP96/02605 <b>(22) International Filing Date:</b> 17 June 1996 (17.06.96) <b>(30) Priority Data:</b> 95201656.6 19 June 1995 (19.06.95) EP <b>(34) Countries for which the regional or international application was filed:</b> AT et al. <b>(71) Applicant (for all designated States except US):</b> AKZO NOBEL N.V. [NL/NL]; Velperweg 76, NL-6824 BM Arnhem (NL). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> VERHEIJDEN, Gijsbertus, Franciscus, Maria [NL/NL]; Heischouw 7, NL-5345 XT Oss (NL). BOOTS, Anna, Maria, Helena [NL/NL]; Verlengde Torenstraat 10, NL-5366 AV Megen (NL). <b>(74) Agent:</b> OGILVIE-EMANUELSON, C.; Postbus 20, NL-5340 BH Oss (NL).		<b>(81) Designated States:</b> AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> NOVEL PEPTIDES FOR USE IN TREATMENT OF T-CELL MEDIATED CARTILAGE DESTRUCTION IN AUTOIMMUNE DISEASES  <b>(57) Abstract</b>  The invention relates to the use of novel peptides in a peptide-induced tolerance therapy for the induction of tolerance to autoaggressive T cells associated with T-cell mediated articular cartilage destruction in autoimmune diseases, more specifically arthritis. The invention furthermore embraces pharmaceutical compositions comprising said peptides and a diagnostic method for the detection of autoreactive T cells in a test sample, said T cells being associated with T-cell mediated articular cartilage destruction in autoimmune diseases and test kits to be used in said method.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Larvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

Novel Peptides For Use In Treatment Of T-Cell Mediated Cartilage Destruction In  
Autoimmune Diseases

5

The invention relates to novel peptides and their use in treatment of T-cell mediated articular cartilage destruction in autoimmune diseases.

More specifically, the invention relates to the use of said novel peptides in a peptide-induced tolerance therapy for the induction of tolerance to autoaggressive T cells associated with T-cell mediated articular cartilage destruction in autoimmune diseases, more specifically arthritis and in particular reumatoid arthritis.

The invention furthermore embraces pharmaceutical compositions comprising said peptides and a diagnostic method for the detection of autoreactive T cells in a test sample, said T cells being associated with T-cell mediated articular cartilage destruction in autoimmune diseases and test kits to be used in said method.

The immune system is based on the discrimination between foreign antigens (non-self antigens) and autoantigens (self-antigens, derived from the individuals own body) achieved by a build in tolerance against the autoantigens.

The immune system protects individuals against foreign antigens and responds to exposure to a foreign antigen by activating specific cells such as T- and B lymphocytes and by producing soluble factors like cytokines, antibodies and complement factors. The antigen to which the immune system responds is processed by the antigen presenting cells (APCs) and a fragment of the antigen is expressed on the cell surface associated with a major histocompatibility complex (MHC) class II glycoprotein. The MHC-glycoprotein-antigen-fragment complex is presented to a T cell which by virtue of its T cell receptor recognizes the antigen fragment conjointly with the MHC class II protein to which it is bound. The T cell becomes activated, i.e. proliferates and/or produces cytokines, resulting in the expansion of the activated T cells directed to the antigen under attack (Grey et al., Sci. Am., 261:38-46, 1989).

Self antigens are also continuously processed and presented as antigen fragments by the MHC glycoproteins to T cells (Jardetsky et al., Nature 353:326-329, 1991). Under normal circumstances the immune system is tolerant to self antigens and activation of the

immune response by these self antigens is avoided. Thus, self recognition is intrinsic to the immune system.

When tolerance to self antigens is lost, the immune system becomes activated against one or more self antigens, resulting in the activation of autoreactive T cells and the production of autoantibodies. This phenomenon is referred to as autoimmunity. As the immune response in general is destructive, i.e. meant to destroy the invasive foreign antigen, autoimmune responses can cause destruction of the body's own tissue.

The contribution of T cells to autoimmune diseases has been established by several studies. In mice, experimental autoimmune encephalomyelitis (EAE) is mediated by a highly restricted group of T cells, linked by their specificity for a single epitope of myelin basic protein (MBP) complexed to an MHC class II molecule. In the Lewis rat, a species with high susceptibility to various autoimmune diseases, disease has been shown to be mediated by T cells. In humans autoimmune diseases are also thought to be associated with the development of auto-aggressive T cells.

A destructive autoimmune response has been implicated in various diseases such as rheumatoid arthritis (RA), in which the integrity of articular cartilage is destroyed by a chronic inflammatory process resulting from the presence of large numbers of activated lymphocytes and MHC class II expressing cells. The mere presence of cartilage appears to be sufficient for sustaining the local inflammatory response: it has been shown that cartilage degradation is associated with the activity of cartilage-responsive autoreactive T cells in RA (Sigall et al., Clin. Exp. Rheumat. 6:59, 1988; Glant et al., Biochem. Soc. Trans. 18:796, 1990; Burmester et al., Rheumatoid arthritis Smolen, Kalden, Maini (Eds) Springer-Verlag Berlin Heidelberg, 1992). Furthermore, removal of cartilage from RA patients by surgery was shown to reduce the inflammatory process. The cartilage proteins are therefore considered to be target autoantigens which are competent of stimulating T cells. Activation of these autoreactive T cells leads to development of autoimmune disease.

The inflammatory response resulting in the destruction of the cartilage can be treated by steroid drugs. However, these drugs are immunosuppressive drugs that are nonspecific and have toxic side effects. The disadvantages of nonspecific immunosuppression makes this a highly unfavourable therapy.

An antigen-specific, nontoxic immunosuppression therapy would provide a very attractive alternative for the nonspecific immunosuppression. This antigen-specific therapy involves the treatment of patients with MHC Class II binding T-cell reactive peptides derived from the autoantigen. These MHC Class II binding T-cell reactive peptides correspond to T cell epitopes of the target autoantigen and can be used to induce specific T cell tolerance both to the administered peptides and the autoantigen. To effectively use the peptide-induced tolerance therapy to treat the T cell mediated articular cartilage destruction, there is a great need for MHC Class II binding T cell-reactive peptides which can desensitize patients against the self antigen that is activating the T cells responsible for the inflammatory process.

The present invention provides for such MHC Class II binding T-cell reactive peptides, that are suitable for use in a peptide-induced tolerance therapy for the induction of tolerance to autoaggressive T cells associated with T-cell mediated cartilage destruction in autoimmune diseases. More specifically, the present invention provides MHC Class II binding T-cell reactive peptides which are very suitable for use in a peptide-induced tolerance therapy for the induction of tolerance to autoaggressive T cells associated with T-cell mediated cartilage destruction in arthritis, in particular reumatoid arthritis.

The peptides according to the invention have an amino acid sequence of 13 to 55 amino acid residues, characterized in that said peptides comprise at least the amino acid sequence (SEQ ID No:1)

AGWLR<sub>1</sub>DR<sub>2</sub>R<sub>3</sub>R<sub>4</sub>R<sub>5</sub>YPI

in which R<sub>1</sub> is A or S; R<sub>2</sub> is Q, R or G; R<sub>3</sub> is T or S; R<sub>4</sub> is V or L; and R<sub>5</sub> is R or Q.

More specifically, the peptides according to the invention comprise the amino acid sequence (SEQ ID No:2)

AGWLR<sub>1</sub>DR<sub>2</sub>R<sub>3</sub>LR<sub>5</sub>YPI

in which R<sub>1</sub> is A or S; R<sub>2</sub> is Q, R or G; R<sub>3</sub> is T or S; and R<sub>5</sub> is R or Q.

In particular, the peptides according to the invention comprise at least one of the amino acid sequences AGWLADQTVRYPI (SEQ ID No:3), AGWLADRSVRYPI (SEQ ID No:4), AGWLADGSLRYPI (SEQ ID No:5) or AGWLSDGSVQYPI (SEQ ID No:6) or combinations thereof.

5 Preferably the peptides according to the invention have an amino acid sequence of 13-35 amino acid residues, more preferably 13-25 amino acid residues. Highly preferred are peptides having an amino acid sequence of 13-19 residues. Particularly preferred are the peptides consisting of amino acid sequence AGWLADQTVRYPI (SEQ ID No:3), AGWLADRSVRYPI (SEQ ID No:4), AGWLADGSLRYPI (SEQ ID No:5) and  
10 AGWLSDGSVQYPI (SEQ ID No:6).

The peptides according to the invention are also understood to comprise multimers, such as for example a dimer or a trimer, which are build up from monomeric building blocks formed by the peptides according to the invention. These monomeric building blocks optionally can be separated by spacer residues. The multimers according to the invention  
15 have the advantage that they provide a multitude of T-cell reactive peptides.

The present invention resides in the fact that the peptides according to the invention resemble MHC Class II binding T-cell epitopes present on autoantigenic proteins which are constituents of the human articular cartilage. More specifically, the peptides according to  
20 the invention resemble MHC Class II binding T-cell epitopes present on the large aggregating proteoglycan of human articular cartilage, human aggrecan (HAG) and human cartilage link protein (HCLP).

It was surprisingly found that the amino acid residues 201-213, 299-311 and 623-635 of the primary structure of HAG (starting from the methionine in the signal sequence)  
25 as well as the amino acid residues 207-219 of the primary structure of HCLP (starting from the methionine in the signal sequence) display MHC Class II binding T-cell epitopes which are recognized by cartilage-responsive autoaggressive T cells associated with the destruction of articular cartilage in autoimmune diseases, more specific arthritis, in particular rheumatoid arthritis. The primary structures of HAG and HCLP have been  
30 described in Doege et al., J. Biol. Chem. Vol. 266, no. 2: 894-902 (1991) and Dudhia et al., Nucl. Acid Res., Vol. 18, no. 5: 1292 (1990) respectively.

Although articular cartilage proteins are considered to be the target autoantigens competent of stimulating autoaggressive T cells involved in the destruction of articular

cartilage in autoimmune diseases, it was not until the present invention that these MHC Class II binding T-cell epitopes associated with cartilage-responsive autoreactive T cells have been identified on the cartilage proteins, in particular on HAG and HCLP. The peptides according to the invention resemble these MHC Class II binding T-cell epitopes, thus providing T-cell reactive peptides which can be used in the peptide-induced T-cell tolerance therapy. Accordingly, patients can be treated with the peptides according to the invention to induce specific T-cell tolerance not only to the administered peptides but to the target autoantigens HAG and HCLP as well. As other components of the immune system are not affected by the peptides according to the invention, the immune system of the patient will remain intact and will be able to protect the patient against other infections.

Thus, the peptides according to the invention provide a very attractive alternative for the classic steroid drugs in the treatment of T-cell mediated destruction of articular cartilage in autoimmune diseases, more specific arthritis, in particular rheumatoid arthritis.

Peptides according to the invention have been described. Perin et al, FEBS Letters 206:73 (1986) describes the structural relationship between link proteins and proteoglycan monomers and discloses a peptide fragment obtained after tryptic digestion of the link protein. The peptide fragment has the amino acid sequence SSAGWLADRSVRYPIISKARNXGG. Goetinck et al, J. Cell Biol. 105:2403-2408 (1987) discloses the peptides NAGWLSDGSVQYPITKPREP and DAGWLADGHSVRYPIISRPRKR which correspond to the amino acid residues Asn<sup>207</sup>-Pro<sup>226</sup> and Asp<sup>306</sup>-Arg<sup>325</sup> respectively of the primary structure of link protein. Said peptides were synthesized to study the interactions between link protein and hyaluronic acid and said amino acid residues were found to be involved in the binding of link protein to hyaluronic acid. Neame et al, J. Biol. Chem. 261(8):3519-3535, (1986) describes the elucidation of the primary structure of link protein from rat chondrosarcoma proteoglycan aggregate. Analysis of a tryptic digest of the link protein revealed a fragment having the amino acid sequence GGLDWCNAGWLSDGSVQYPITKPR. Perides et al, J. Biol. Chem., Vol. 264, no. 10: 5981-5987 (1989) describes the isolation and partial characterization of a glial hyaluronate-binding protein (GHBP). Tryptic digestion of GHBP results in several peptide fragments, one of which having the amino acid sequence EQLFAAYEDGFEQC DAGWLADQTVRYPIRAPRVGCY.

None of these publications however disclose that said peptides display MHC Class II binding T-cell epitopes which are recognized by cartilage-responsive autoaggressive T cells involved in the destruction of articular cartilage in immune diseases. Nor do these publications suggest or hint towards the use of said peptides in a peptide-induced T-cell tolerance therapy for the induction of tolerance to autoaggressive T cells associated with T-cell mediated destruction of the articular cartilage in autoimmune diseases.

10 The peptides according to the invention can be prepared by well known organic chemical methods for peptide synthesis such as, for example, solid-phase peptide synthesis described for instance in J. Amer. Chem. Soc. 85:2149 (1963) and Int. J. Peptide Protein Res. 35:161-214 (1990).

15 The peptides according to the invention can also be prepared by recombinant DNA techniques. A nucleic acid sequence coding for a peptide according to the invention or a multimer of said peptides is inserted into an expression vector. Suitable expression vectors are, amongst others, plasmids, cosmids, virusses and YAC's (Yeast Artificial Chromosomes) which comprise the necessary control regions for replication and expression. The expression vector can be brought to expression in a host cell. Suitable host  
20 cells are, for instance, bacteria, yeast cells and mammalian cells. Such techniques are well known in the art, see for instance Sambrooke et al, Molecular Cloning: a Laboratory Manual, Cold Spring Harbor laboratory Press, Cold Spring Harbor, 1989.

25 According to the invention, patients suffering from T-cell mediated destruction of the articular cartilage can be treated with a therapeutical composition comprizing one or more peptides according to the invention and a pharmaceutical acceptable carrier. Administration of the pharmaceutical composition according to the invention will induce tolerance of the specific autoreactive T cells of these patients to the autoantigenic proteins in the articular cartilage under attack and other self antigens which display the identified  
30 MHC Class II binding T cell epitopes characterized by one of the amino acid sequences of SEQ ID NO:1-6. More specifically, administration of the pharmaceutical composition according to the invention will induce tolerance of the specific autoaggressive T cells to the



autoantigens HAG end HCLP. The induced tolerance thus will lead to a reduction of the local inflammatory response in the articular cartilage under attack.

Very suitable peptides to be used in a pharmaceutical composition according to the invention are the peptides having 13-55, preferably 13-35, more preferably 13-25, highly preferably 13-19 amino acid residues characterized in that said peptides comprise at least one of the amino acid sequences given in SEQ ID NO:1 and 2.

Specifically preferred in a pharmaceutical composition according to the invention are the peptides having 13-55, preferably 13-35, more preferably 13-25, highly preferably 13-19 amino acid residues characterized in that said peptides comprise at least one of the amino acid sequences given in SEQ ID NO:3-6.

Highly preferred in a pharmaceutical composition according to the invention are peptides having 13 amino acid residues characterized in that said peptides have the amino acid sequence given in SEQ ID NO:1 and 2.

Most preferred in a pharmaceutical composition according to the invention are the peptides having 13 amino acid residues with amino acid sequence of SEQ ID NO: 3, 4, 5 or 6.

The peptides according to the invention have the advantage that they have a specific effect on the autoreactive T cells thus leaving the other components of the immune system intact as compared to the nonspecific suppressive effect of the immunosuppressive steroid drugs. Treatment with the peptides according to the invention will be safe and no toxic side effects will occur.

Tolerance can be attained by administering high or low doses of peptides according to the invention. The amount of peptide will depend on the route of administration, the time of administration, the age of the patient as well as general health conditions and diet.

In general, a dosage of 0.01 to 1000  $\mu\text{g}$  of peptide per kg body weight, preferably 0.5 to 500  $\mu\text{g}$ , more preferably 0.1 to 100  $\mu\text{g}$  of peptide can be used.

Pharmaceutical acceptable carriers are well known to those skilled in the art and include, for example, sterile saline, lactose, sucrose, calcium phosphate, gelatin, dextrin, agar, pectin, peanut oil, olive oil, sesame oil and water. Other carriers may be, for example MHC class II molecules, if desired embedded in liposomes.

In addition the pharmaceutical composition according to the invention may comprise one or more adjuvants. Suitable adjuvants include, amongst others, aluminium hydroxide, aluminium phosphate, amphigen, tocopherols, monophosphoryl lipid A,

muramyl dipeptide and saponins such as Quill A. The amount of adjuvant depends on the nature of the adjuvant itself.

Furthermore the pharmaceutical composition according to the invention may comprise one or more stabilizers such as, for example, carbohydrates including sorbitol, mannitol, starch, sucrosextrin and glucose, proteins such as albumin or casein, and buffers like alkaline phosphates.

Suitable administration routes are intramuscular injections, subcutaneous injections, intravenous injections or intraperitoneal injections, oral administration and nasal sprays.

The peptides according to the invention are also very suitable for use in a diagnostic method to detect the presence of activated autoreactive T cells involved in the chronic inflammation and destruction of the articular cartilage.

The diagnostic method according to the invention comprises the following steps:

- a) isolation of the peripheral blood mononuclear cells (PBMC) from a blood sample of an individual,
- b) culture said PBMC under suitable conditions,
- c) incubation of said PBMC culture in the presence of the autoantigen or one or more peptides derived thereof according to the invention, and
- d) detection of a response of T cells, for example a proliferative response, indicating the presence of activated autoreactive T cells in the individual.

The detection of a proliferative response of T cells can be detected by, for example, the incorporation of  $^3\text{H}$ -thymidine.

Also within the scope of the invention are test kits which comprise one or more peptides according to the invention. These test kits are suitable for use in a diagnostic method according to the invention.

The following examples are illustrative for the invention and should in no way be interpreted as limiting the scope of the invention.

## EXAMPLES

### METHODS

#### **Patients**

- 5 Peripheral blood mononuclear cells (PBMC) from patients who were diagnosed as suffering from RA according to the American Rheumatism Association (ARA) criteria (Arnett et al., Arthritis Rheum. 31:315, 1988) were collected. The severity of disease of RA patients ranged from stage I - IV as determined by Röntgenscore. During the course of studies patients were treated with indomethacine, methotrexate, glucocorticoids or non-steroidal anti-inflammatory drugs
- 10

#### **MHC typing**

- Patient PBMC chromosomal DNA extracts were analysed using the Dynal DR 'low resolution' SSP kit. DR4 subtyping was performed using the Dynal DRB1\*04-SSP kit.
- 15 Interpretation of MHC typing data was done in collaboration with the University Transfusion service, Radboud hospital, Nijmegen, The Netherlands.

#### **Peptides**

- Peptides according to the invention and a control peptide IHA(307-319)F, PKFVKQNTLKAT (SEQ ID NO:7), were synthesized by solid-phase peptide synthesis. In brief, peptides with free amino- and carboxy termini were synthesized on a fully automated Milligen 9050 synthesizer, using Fmoc/tBu protected activated esters on PEG-PS resins. The peptides were cleaved off the resin and deprotected using TFA/Thioanisole/Ethanedithiol/Anisole 90/5/3/2 or TFA/H<sub>2</sub>O 95/5 by volume. The peptides were purified by preparative HPLC, converted into acetate salts with Dowex Ac-resin or into chloride salts and lyophilized. Purity and identity of the peptides were assessed by reverse phase HPLC and FAB-MS, respectively. The peptides used in this study are listed in Table 1. An N-terminal biotinylated Influenza Haemagglutinine derived peptide IHA(307-319)F, in which the third residue (Y) was replaced by F, (biotin-NH-(CH<sub>2</sub>)<sub>5</sub>-CO-PKFVKQNTLKLAT, SEQ ID No. 7), was used as marker peptide in the binding studies with DR4Dw4 (DRB1\*0401). In order to prevent interference of the biotin group with peptide binding, biotin was attached via a spacer to the amino-terminus of the marker peptide.
- 20
- 25
- 30

Table 1: the peptides synthesized

Peptide	Sequence	HPLC purity	SEQ ID NO
HAG1	AGWLADQTVRYPI	> 90%	3
HAG2	AGWLADRSVRYPI	> 90%	4
HAG3	AGWLADGSLRYPI	> 90%	5
HCLP1	AGWLSGDSVQYPI	> 90%	6
IHA(307-319)F	PKFVKQNTLKLAT	> 90%	7

#### Affinity purification of HLA-DR molecules

- Two EBV-transformed B-cell lines, BSM (typed as DR4 [DRB1\*0401] and BM92 (typed as DR4 [DRB1\*0404) were provided by Dr. M. Oudshoorn from the Academic Hospital Leiden, the Netherlands. The cells were cultured in Dulbecco's modified eagles minimal essential medium DMEM/HAM's F12 (Gibco Laboratories, Grand Island, NY) supplemented with 10% FCS (Hyclone Laboratories), 1% non-essential amino acids (ICI), L-glutamine, 2-ME and antibiotics. Cells were routinely passaged every 2-3 days in a 1:2 ratio. Cells were harvested and thereafter washed three times in phosphate buffer saline (PBS) (4°C) containing 1 mM PMSF. Cell pellets were stored at -70°C until use. HLA-DR expressing cells were thawed and lysed on ice for 30 minutes in PBS, 1% NP-40, 1 mM AEBSF (Calbiochem). The lysate was cleared of nuclei and debris by centrifugation at 15.000 rpm (Sorvall, SS34 rotor) for 30 minutes.

HLA-DR molecules were affinity purified from cell lysates using monoclonal antibody L243 (ATCC), directed against a nonpolymorphic determinant on the DR-complex (Lampson et al., J. Immunol. 125:293, 1980). Protein G sepharose purified L243 was coupled to NHS-Sepharose 4 FF (Pharmacia) according to the manufactures instructions. The cleared cell-lysate was passed through a 0.45 µm filter and added to L243-NHS-sepharose beads. After overnight incubation, the beads were transferred to a column and washed with five volumes PBS, 1% NP-40; 5 volumes PBS, 0.5% NP-40; 15 volumes PBS, 0.5% NP-40, 0.1% SDS; 5 volumes PBS, 0.05% NP-40; 5 volumes PBS, 1% n-octyl-glucoside (Sigma, St. Louis, USA) and 5 volumes 50 mM diethylamine (Fluka), 150 mM NaCl, 1% n-octyl-glucoside pH=8.0. HLA-DR molecules were eluted with 50 mM diethylamine, 150 mM NaCl, 1% n-octyl-glucoside pH=11. Immediately after collection, the fractions were neutralised with 2M glycine pH=4.8. Collected fractions were

analysed on SDS-PAGE under non-reducing conditions followed by silver staining. Fractions containing purified HLA-DR were pooled and subsequently concentrated by ultrafiltration over a 30 kD cut-off membrane.

#### 5 **Peptide HLA-DR binding assay**

The peptide binding studies were performed using a semi-quantitative binding assay as described previously (Joosten et al., *Int. Immunol.* 6:751, 1994). Purified HLA-DR molecules (0.05-5  $\mu$ M) were incubated at pH=5.0 with 50 nM biotinylated marker peptide (IHA(307-319)F) and a concentration range of competitor peptide (peptides HAG1, HAG2, HAG3 and HCLP1) in a final volume of 25  $\mu$ l binding buffer (PBS, 1 mM AEBSF, 1 mM N-ethyl maleimide, 8 mM EDTA, 10  $\mu$ M pepstatin A, 0.01%  $\text{NaN}_3$ , 0.05% NP-40 and 5% DMSO).

After approximately 48 hours incubation at room temperature, bound and unbound marker peptides were separated by SDS-PAGE under non-reducing conditions. Proteins were blotted onto a nitro-cellulose membrane (Hybond ECL, Amersham, U.K.) using a semi-dry blotting system (Pharmacia). The nitrocellulose filters were blocked with 0.5% DNA blocking reagents (Boehringer Mannheim, Germany) in 0.1 M maleic acid pH=7.5, 150 mM NaCl. After 1 hour, the filters were washed in PBS, 0.05% Tween 20 (Sigma, St. Louis, USA) and incubated with Streptavidin-HRP (Southern Biotechnology) in a 1:40.000 dilution. Biotinylated peptides were detected by enhanced chemoluminescence using a Western Blot ECL kit (Amersham, U.K.) according to the manufactures instructions. Preflashed films (hyperfilm-ECL, Amersham, U.K.) were exposed for 30 minutes.

The affinity of a the peptides according to the invention for binding DRB1\*0401 or DRB1\*0404-encoded molecules was related to competition with the marker peptide. This relative binding affinity  $\text{IC}_{50}$  ( $^{\circ}\text{IC}_{50}$ ) was defined as the peptide concentration at which the signal of the biotinylated marker peptide was reduced to 50% by visual inspection of the signal in absence of the competitor peptide.

#### **Proliferative responses of blood mononuclear cells**

The peptides HAG1, HAG2, HAG3 and HCLP1 were tested for their capacity to induce proliferative responses in PBMC. Proliferative assays involving PBMC have been used previously to measure activation of antigen-specific, class II restricted T-cell responses (Good et al, *Proc. Natl. Acad.Sci USA* 85:1199, 1988)

PBMC obtained from heparinized venous peripheral blood were isolated by standard centrifugation on a Ficoll-Paque gradient. Cells were cultured in three- or four-fold at a concentration of  $1.5 \times 10^5$  cells/well in DMEM/Ham's F12 medium supplemented with 10% heat-inactivated pooled human serum, L-glutamine, 2-ME and antibiotics in flatbottomed microtiter plates. Cells were incubated in medium alone or in the presence of PHA (2.5  $\mu\text{g/ml}$ ) or in the presence of antigens, including the chicken proteoglycan fraction, the chicken collagen fraction, sonicated *Mycobacterium tuberculosis* or the peptides HAG1, HAG2, HAG3 and HCLP1 in concentrations of 50  $\mu\text{g/ml}$ , 5  $\mu\text{g/ml}$  or 0.5  $\mu\text{g/ml}$ . Cultures were incubated in a total volume of 210  $\mu\text{l}$  for 4, 5, 6 or 7 days at 37 °C in a humidified atmosphere of 5%  $\text{CO}_2$ . Cultures were pulsed with 0.5  $\mu\text{Ci}$  ( $1.85 \times 10^4$  Bq) [ $^3\text{H}$ ]Thymidine ([ $^3\text{H}$ ]TdR) for the last 18 hours of cell culture. Cells were harvested on glassfibre filters and [ $^3\text{H}$ ]TdR incorporation was measured by gasscintillation. Note that counting by gasscintillation is fivefold less efficient compared to liquid scintillation. Therefor, filters were measured for 5 min (Packard Matrix 96  $\beta$ -counter; Meriden CT).

## RESULTS

### Peptide HLA-DR binding assay

Binding of the peptides HAG1, HAG2, HAG3 and HCLP1 to DR4 (DRB1\*0401) and DR4(DRB1\*0404) was performed in a direct semi-quantitative competition binding assay using affinity purified HLA-DR molecules. The results are shown in Table 2. As can be seen from Table 2, all peptides bind to DR4(DRB1\*0401) and are able to compete with the marker peptide.

Table 2: Peptide binding to HLA-DRB1\*0401 encoded molecules

Peptide	Sequence	DRB1*0401 <sup>o</sup> IC <sub>50</sub>
HAG1	AGWLADQTVRYPI	++
HAG2	AGWLADRSVRYPI	++
HAG3	AGWLADGSLRYPI	++
HCLP1	AGWLSDGSVQYPI	+

++ = good binder, <sup>o</sup>IC<sub>50</sub> between 1-10  $\mu$ M; + = intermediate binder, <sup>o</sup>IC<sub>50</sub> between 10-100  $\mu$ M; +/- = poor binder, <sup>o</sup>IC<sub>50</sub> between 100-1000  $\mu$ M; - = non-binder, <sup>o</sup>IC<sub>50</sub> exceeds 1000  $\mu$ M

5

### PBMC proliferative assay

In order to determine T-cell reactivity to the peptides HAG1, HAG2, HAG3 and HCLP1, the PBMC proliferative response in RA patients was analyzed. Table 3 only represents the values obtained at 50  $\mu$ g/ml. Results are expressed as the mean of three or four measurements (count per 5 min). Standard error of the mean did not exceed 30%. Underlined values are regarded positive (counts per 5 min > 1000 and stimulation index SI > 2)). Most patients responded to at least one of the peptides according to the invention, indicating that the peptides according to the invention are recognized by autoaggressive T-cells associated with autoimmune disease.

15

Table 3: Proliferative responses of PBMC from RA patients to the peptides.

Donors Peptides	191 (RA)	209 (RA)	227 (RA)
HAG1	<u>1177</u>	<u>1336</u>	1352
HAG2	<u>1061</u>	<u>1115</u>	ND
HAG3	233	<u>1094</u>	ND
HCLP1	ND	<u>1503</u>	<u>1964</u>
BG	320	405	833

ND = not done, BG = back ground

## SEQUENCE LISTING

## 5 (1) GENERAL INFORMATION:

## (i) APPLICANT:

- (A) NAME: AKZO NOBEL N.V.  
(B) STREET: Velperweg 76  
(C) CITY: Arnhem  
(E) COUNTRY: The netherlands  
(F) POSTAL CODE (ZIP): 6824 BM  
(G) TELEPHONE: 04120-66376  
(H) TELEFAX: 04120-50592  
(I) TELEX: 37503 akpha nl

(ii) TITLE OF INVENTION: Novel Peptides For Use In Treatment Of T-Cell Mediated Cartilage Destruction In Autoimmune Diseases

(iii) NUMBER OF SEQUENCES: 7

## (iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)

## (2) INFORMATION FOR SEQ ID NO: 1:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 13 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

## (ix) FEATURE:

- (A) NAME/KEY: Peptide  
(B) LOCATION: 1..13  
(D) OTHER INFORMATION: /label= Xaa  
/note= "Xaa on pos 5 = A or S; Xaa on pos 7 = Q, R  
or G; Xaa on pos 8 = T or S; Xaa on pos 9 = V or  
L; Xaa on pos 10 = R or Q"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

Ala Gly Trp Leu Xaa Asp Xaa Xaa Xaa Tyr Pro Ile  
1 5 10

## (2) INFORMATION FOR SEQ ID NO: 2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 13 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

## (ix) FEATURE:

- (A) NAME/KEY: Peptide



(B) LOCATION: 1..13

(D) OTHER INFORMATION: /label= PEPTIDE

/note= "Xaa on pos 5 = A or S; Xaa on pos 7 = Q, R  
org; Xaa on pos 8 = T or S; Xaa on pos 10 = R or  
Q"

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

10

Ala Gly Trp Leu Xaa Asp Xaa Xaa Leu Xaa Tyr Pro Ile  
1 5 10

(2) INFORMATION FOR SEQ ID NO: 3:

15

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 13 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

20

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

30

Ala Gly Trp Leu Ala Asp Gln Thr Val Arg Tyr Pro Ile  
1 5 10

(2) INFORMATION FOR SEQ ID NO: 4:

35

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 13 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

40

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

50

Ala Gly Trp Leu Ala Asp Arg Ser Val Arg Tyr Pro Ile  
1 5 10

(2) INFORMATION FOR SEQ ID NO: 5:

55

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 13 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

60

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

65

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Ala Gly Trp Leu Ala Asp Gly Ser Leu Arg Tyr Pro Ile  
1 5 10

## (2) INFORMATION FOR SEQ ID NO: 6:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 13 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Ala Gly Trp Leu Ser Asp Gly Ser Val Gln Tyr Pro Ile  
1 5 10

## (2) INFORMATION FOR SEQ ID NO: 7:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 13 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

Pro Lys Phe Val Lys Gln Asn Thr Leu Lys Leu Ala Thr  
1 5 10

CLAIMS:

1. Peptide having 13-55 amino acid residues characterized in that said peptide comprises the amino acid sequence

5

$$A\ G\ W\ L\ R_1\ D\ R_2\ R_3\ R_4\ R_5\ Y\ P\ I$$

in which  $R_1 = A, S$

 $R_2 = Q, R, G$ 

10

 $R_3 = T, S$  $R_4 = V, L$  $R_5 = R, Q.$ 

with the provision that the peptide is not SSAGWLADRSVRYPIISKARPNXGG,  
NAGWLSDGSVQYPITKPREP, DAGWLADGHSVRYPISRPRKR,  
15 GGLDWCNAGWLSDGSVQYPITKPR or  
EQLFAAYEDGFEQCDAGWLADQTVRYPIRAPRVGCY.

2. Peptide having 13-55 amino acid residues characterized in that said peptide comprises at least the amino acid sequence

20

$$A\ G\ W\ L\ R_1\ D\ R_2\ R_3\ L\ R_5\ Y\ P\ I$$

in which  $R_1 = A, S$

25

 $R_2 = Q, R, G$  $R_3 = T, S$  $R_5 = R, Q.$ 

3. Peptide having 13-55 amino acid residues characterized in that said peptide comprises at least one of the amino acid sequences AGWLADQTVRYPI,  
30 AGWLADRSVRYPI, AGWLSDGSVQYPI and AGWLADGSLRYPI.

4. Peptide consisting of one of the amino acid sequences AGWLADQTVRYPI, AGWLADRSVRYPI, AGWLSDGSVQYPI and AGWLADGSLRYPI.
5. Peptide having 13-55 amino acid residues and comprizing the amino acid sequence A G W L R<sub>1</sub> D R<sub>2</sub> R<sub>3</sub> R<sub>4</sub> R<sub>5</sub> Y P I in which R<sub>1</sub> = A, S, R<sub>2</sub> = Q, R, G, R<sub>3</sub> = T, S, R<sub>4</sub> = V, L, and R<sub>5</sub> = R, Q, for use as a medicament.
6. Pharmaceutical preparation comprizing a peptide having 13-55 amino acid residues, said peptide comprizing the amino acid sequence A G W L R<sub>1</sub> D R<sub>2</sub> R<sub>3</sub> R<sub>4</sub> R<sub>5</sub> Y P I in which R<sub>1</sub> = A, S, R<sub>2</sub> = Q, R, G, R<sub>3</sub> = T, S, R<sub>4</sub> = V, L, and R<sub>5</sub> = R, Q, and a pharmaceutical acceptable carrier.
7. Pharmaceutical preparation comprizing a peptide having 13-55 amino acid residues, said peptide comprizing the amino acid sequence A G W L R<sub>1</sub> D R<sub>2</sub> R<sub>3</sub> L R<sub>5</sub> Y P I in which R<sub>1</sub> = A, S, R<sub>2</sub> = Q, R, G, R<sub>3</sub> = T, S and R<sub>5</sub> = R, Q, and a pharmaceutical acceptable carrier.
8. Pharmaceutical preparation comprizing a peptide having 13-55 amino acid residues, said peptide comprizing at least one of the amino acid sequences AGWLADQTVRYPI, AGWLADRSVRYPI, AGWLSDGSVQYPI and AGWLADGSLRYPI.
9. Pharmaceutical preparation comprizing at least one of the peptides AGWLADQTVRYPI, AGWLADRSVRYPI, AGWLADGSLRYPI and AGWLSDGSVQYPI and a pharmaceutical acceptable carrier.
10. Use of a peptide having 13-55 amino acid residues, said peptide comprizing the amino acid sequence A G W L R<sub>1</sub> D R<sub>2</sub> R<sub>3</sub> R<sub>4</sub> R<sub>5</sub> Y P I in which R<sub>1</sub> = A, S, R<sub>2</sub> = Q, R, G, R<sub>3</sub> = T, S, R<sub>4</sub> = V, L, and R<sub>5</sub> = R, Q, for the manufacture of a pharmaceutical preparation for use in a peptide-induced tolerance therapy for the induction of tolerance to autoaggressive T cells associated with T-cell mediated articular cartilage destruction in autoimmune diseases.

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 6 C07K14/47 A61K38/10 A61K38/16

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>IMMUNOLOGY,  vol. 78, no. 4, April 1993, OXFORD,  ENGLAND,  pages 586-591, XP002013660  J A GOODACRE ET AL.: "Human cartilage  aggrecan CS1 region contains cryptic  T-cell recognition sites"  see the whole document</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	1-10

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

18 September 1996

Date of mailing of the international search report

02.10.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Masturzo, P

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CLIN. IMMUNOL. IMMUNOPATHOL., vol. 64, no. 2, August 1992, NEW YORK, USA, pages 121-128, XP002013661 M G DANIELI ET AL.: "Juvenile rheumatoid arthritis patients manifest immune reactivity to the mycobacterial 65-kDa heat shock protein, to its 180-188 peptide, and to a partially homologous peptide of the proteoglycan link protein" see page 122 ---	1-10
A	BIOCH. SOC. TRANS., vol. 18, no. 5, October 1990, LONDON, page 955 XP002013662 N J GOODSTONE ET AL.: "Responses of T-cells from patients with inflammatory arthritis to human cartilage antigens" see the whole document ---	1-10
X	J CELL BIOLOGY, vol. 105, no. 5, November 1987, NEW YORK, pages 2403-2408, XP002013663 P F GOETINK ET AL.: "The tandemly repeated sequences of cartilage link protein contain the sites for interaction with hyaluronic acid" cited in the application see the whole disclosure, especially the peptides listed on page 2404 ---	2,3,5,6, 8,10
X	JOURNAL OF BIOLOGICAL CHEMISTRY (MICROFILMS), vol. 261, no. 8, 15 March 1986, MD US, pages 353519-3535, XP002013685 P J NEAME ET AL.: "The primary structure of link protein from rat chondrosarcoma proteoglycan aggregate" cited in the application see the whole disclosure, especially Figure 1 on page 3521 ---	2,3,5,6, 8,10
X	JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 264, no. 10, 5 April 1989, MD US, pages 5981-5987, XP002013686 G PERIDES ET AL.: "Isolation and partial characterization of a glial hyaluronate-binding protein" cited in the application see the whole disclosure, especially the peptide S6a on page 5986 ---	2,3,5,6, 8,10

-/--

## INTERNATIONAL SEARCH REPORT

Int. Patent Application No.

PC1/EP 96/02605

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>CHEMICAL ABSTRACTS, vol. 105, no. 23, 8 December 1986 Columbus, Ohio, US; abstract no. 2050003n, J P PERIN ET AL.: "Structural relationship between link proteins and proteoglycan monomers" page 241; XP002013687 see abstract &amp; FEBS LETTERS, vol. 206, no. 1, 1986, AMSTERDAM NL, pages 73-77, cited in the application -----</p>	<p>2,3,5,6, 8,10</p>